Quick Links

 Patents

City of Hope is pleased to offer licensing opportunities for the patented or patent-pending scientific developments and discoveries. City of Hope is prepared to make appropriate supporting documentation available to parties who express an interest in the commercialization or further development of these technologies. To receive additional information on commercial licensing opportunities please contact Dr. George Megaw, at 626-301-8841.

Diamond, D.J. and York, J.  Immuno-reactive Peptide CTL Epitopes of Human Cytomegalovirus. Patent # 6,074,645, June 13, 2000

Diamond, D. J. and York, J. Immuno-reactive Peptide CTL Epitopes of Human Cytomegalovirus. Patent # 6,156,317, December 5, 2000

Diamond, D.J. Immuno-Reactive Peptide CTL Epitopes of Human Cytomegalovirus. Patent # 6,251,399, June 26, 2001

Diamond, D.J. Immunoreactive peptide CTL epitopes of cytomegalovirus pp150. Patent # 6,544,521, April 8, 2003

Diamond, D.J. Immuno-Reactive Peptide CTL Epitopes of Human Cytomegalovirus. Patent # 6,562,345, May 13, 2003

Diamond, D.J. CTL Epitope Analogs. Patent # 6,632,435. October 14, 2003

Diamond, D.J. Immuno-Reactive Peptide CTL Epitopes of Human Cytomegalovirus. Patent # 6,726,910, April 27, 2004

Diamond, D.J. HCMV-reactive T cells and uses thereof. Patent # 6,727,093, April 27, 2004

Diamond, D.J. Diagnostic Reagents for Human Cytomegalovirus and Methods of use. Patent # 6,733,973, May 11, 2004

Ellenhorn, J. and Diamond, D.J. p53-specific T Cell Receptor for Adoptive Immunotherapy. Patent # 6,770,749, August 3, 2004

Diamond, D.J. Immuno-Reactive Peptide CTL Epitopes of Human Cytomegalovirus. Patent # 6,843,992, January 18, 2005

Diamond, D.J. CTL Epitope Analogs. Patent # 6,951,651, October 4, 2005.

Diamond, D.J. Diagnostic reagents for human cytomegalovirus and methods of use. Patent # 7,160,685, January 9, 2007.

Diamond, D.J. and Wang, Z. Human cytomegalovirus antigens expressed in MVA and methods of use. Patent # 7,163,685, January 16, 2007.

Ellenhorn, J. and Diamond, D.J. Modified vaccinia Ankara expressing p53 in cancer immunotherapy. Patent # 7,256,037, August 14, 2007.

 Search

Go!
Advanced Search Options
News & Publications Search
NCI CCC LogoCity of Hope is one of 40 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute and a recognition of excellence in cancer treatment, research, prevention and education.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HON code of the Healthcare on the Net Foundation.